Brickell Biotech Inc (NASDAQ:BBI)

0.8192
Delayed Data
As of Sep 25
 +0.0392 / +5.03%
Today’s Change
0.71
Today|||52-Week Range
4.29
-45.39%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$23.9M

Company Description

Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.

Contact Information

Brickell Biotech, Inc.
5777 Central Avenue
Boulder Colorado 80301
P:(720) 505-4755
Investor Relations:

Employees

Shareholders

Individual stakeholders7.92%
Mutual fund holders3.85%
Other institutional11.86%

Top Executives

Robert B. BrownChief Executive Officer & Director
Andrew D. SklawerChief Operating Officer & Secretary
R. Michael CarruthersChief Financial Officer
Deepak ChadhaChief Research & Development Officer
Nancy SerettaHead-Clinical Operations